Go to main navigation Navigation menu Skip navigation Home page Search

Sweden launches testbed for clinical trials in cancer care

Vision Zero Cancer and Genomic Medicine Sweden (GMS) join forces with SciLifeLab, public sector authorities, regions, healthcare, academia, industry and patient associations to create an innovation milieu that facilitates the introduction of more precise prevention and treatment in cancer care. The research institute SIR at the SSE is the coordinator Vision Zero Cancer.

Through the call Innovation milieus within Precision Health 2021, The Swedish Innovation Agency, Vinnova, has chosen to invest in 11 innovation milieus in precision health that will pave the way for more prevention, precision, and equity in healthcare and contribute to strengthening Sweden as a life science nation.

"For cancer patients, this is a piece of the puzzle that enables the development of new innovations so that more people can live longer and better. This initiative consolidates Vision Zero Cancer as a national point of contact for system innovation and strengthens our ambition to spread  the Vision Zero globally", says Ebba Hallersjö Hult, co-founder and head of Vision Zero Cancer and Test Bed Sweden.

"GMS is very pleased to participate in this broad consortium that together can move the positions for national clinical studies in cancer in Sweden. At GMS, we are already working on a national, structured implementation of genomics-based precision medicine and we look forward to working together furthering more clinical studies", says Anders Edsjö, Vice Chairman of GMS management team, Section Head and Senior Molecular Pathologist at Clinical Genetics and Pathology, Region Skåne.

The research institute SIR at the Stockholm School of Economics is the coordinator for Vision Zero Cancer and for the new innovation milieu “Test Bed Sweden for Clinical Trials and Implementation of Precision Health in Cancer Care”, which has been granted funding for five years by Vinnova and which will be part of the national strategic innovation program Swelife.

Comprised in the Life Science strategy, the government has a stated ambition that Sweden should be a pioneer for the introduction of precision medicine in healthcare. Predictions suggest that precision medicine is likely to grow primarily in cancer care over the next decade. In 10 years, between 300 and 400 new immunotherapies, targeted drugs and tumour agnostic drugs could be approved.

SSE SIR

Den här hemsidan använder cookies. Genom att använda hemsidan accepterar du dessa cookies samt villkoren beskrivna i vår dataskyddspolicy. Läs mer